Landscape Update
What Changed: Mar 2026 → Jul 2026
Snapshot: 28 Jul 2026
Sources: 25+ articles, ClinicalTrials.gov v2 API
Sources: 25+ articles, ClinicalTrials.gov v2 API
Headline for ACE-723 team
The GPC3 space just got materially hotter. C-CAR031 (AZD7003) published in Nature with 44.4% ORR / 14.2 mo mOS in heavily pretreated aHCC and Ori-C101 became the first GPC3 immune cell therapy globally to enter a confirmatory registration Phase II. Meanwhile the 1L landscape shifted — EMERALD-1 missed final OS, EMERALD-3 confirmed PFS benefit but OS still immature, and rivoceranib/camrelizumab was rejected by FDA for a third time (manufacturing, not efficacy). Your 2L+ competitive window remains open, but the GPC3 differentiation bar just rose.
GPC3 PROGRAMS
C-CAR031 / AZD7003 — Nature publication (15 Jul 2026)
AbelZeta / AstraZeneca Phase 1 (NCT05155189) full results. n=36 heavily pretreated (median 4 prior lines, 94% BCLC-C, 83% extrahepatic mets). ORR 44.4%, DCR 91.7%, mPFS 4.2 mo, mOS 14.2 mo (vs 8–10 mo historical 2L benchmark). CRS 94.4% (mostly G1–2), no ICANS. Updated Phase I data (abstract 1680RO) to be presented at ESMO 2026 (Madrid, Oct). Resistance linked to GPC3 antigen loss and TGFβ elevation.
Ori-C101 (Oricell) — NMPA Phase II clearance (8 Jun 2026)
First GPC3 immune cell therapy globally, and first CAR-T ever for HCC, to enter confirmatory registration Phase II. Randomized, open-label, multicenter, in GPC3+ aHCC after ≥2 prior lines. Prior Ph Ib BEACON: 66.7% ORR at RP2D, mOS 21.4 mo, 12-mo OS 69.3%. Oricell also closed ~$110M pre-IPO in 2026. Trial NCT05652920 record still shows old status — likely a new registration NCT is imminent.
MGC-026 (MacroGenics) — still recruiting
NCT06242470, Phase 1 in advanced solid tumors, last update 5 Feb 2026. Enrollment target 250. No published efficacy readouts yet.
BOXR-1030 (SOTIO) — enrollment capped at 7
NCT05120271 now ACTIVE, NOT RECRUITING (last update Dec 2025) — strategic signal that this GPC3 CAR-T program may be de-prioritized. Watch for divestiture or discontinuation announcement.
REGULATORY
Rivoceranib + Camrelizumab (Elevar/Hengrui) — 3rd FDA CRL (10 Jul 2026)
Third rejection for 1L uHCC based on manufacturing (cGMP) deficiencies, not efficacy. CARES-310 data (mOS 23.8 mo vs 15.2 mo sorafenib) remain intact. Same rivoceranib site passed EU inspection in 2025. Approval delay = window remains for other 1L IO combos. Approved and marketed in China since 2023.
CheckMate 9DW readouts extended (Jul 2026 review)
4-year follow-up: nivo+ipi maintains survival tail. ORR 36%, mOS 23.7 mo (vs 20.6 mo LEN/SOR). ALBI-1 subgroup mOS 35.4 mo. 47% still in ongoing response at 3 yr, mDoR 30.4 mo. Reinforces 1L IO-IO as durable option.
FDA Fast Track / Orphan / RMAT activity in HCC (H1 2026)
RZ-001 (Rznomics) — RMAT for HCC (May 2026). PLT012 (Pilatus) — Fast Track. RCT1213 — Orphan Drug. BGB-B2033 (BeiGene) — Fast Track for advanced HCC (Dec 2025). EvoLiver blood test — Breakthrough Device.
Namodenoson (Can-Fite) — Ph3 HCC, still Fast Track for 2L
Positive PDAC Ph2a accepted at ESMO 2026; HCC Phase 3 progressing. Distinct A3AR MoA for Child-Pugh B HCC.
CONFERENCE READOUTS
ASCO 2026 · ESMO GI 2026
EMERALD-1 (NCT03778957) — final OS negative
Durva + bev + TACE did NOT improve OS vs TACE alone in embolisation-eligible HCC (29.9 vs 33.3 mo, HR 1.10, p=0.470), despite earlier PFS win (15.0 vs 8.2 mo). Reshapes TACE-IO narrative. Status: ACTIVE, NOT RECRUITING (last update 15 Jul 2026).
EMERALD-3 (NCT05301842) — STRIDE + TACE PFS confirmed
STRIDE ± lenvatinib + TACE improved PFS vs TACE (HR 0.71, second cutoff Feb 2026). ORR 40.8% (STRIDE+TACE) and 38.9% (STRIDE+LEN+TACE) vs 27.0% (TACE). OS still immature but trending favorable (HR 0.84). Presented as LBA2 at ESMO GI 2026.
Irpagratinib (ABSK-011, NCT07327034) — enrollment ongoing
FGFR4 inhibitor + atezo Phase 2 (ABSK-011-201) updated data at ESMO GI 2026: encouraging ORR/DCR in FGF19+ HCC monotherapy and combo. Ph2 pivotal (141 pts) recruiting, last update Jan 2026.
Camrelizumab + Rivoceranib + TACE — ASCO 2026 Abstract 4001
Randomized Phase 3 in unresectable HCC. Adds to intermediate-stage combo IO+TKI+TACE evidence.
ACE-723 IMPLICATIONS
Competitive bar for GPC3 in 2L+
The benchmark to beat is now C-CAR031: 44.4% ORR, 14.2 mo mOS in 4L median setting. Ori-C101 goes further: 66.7% ORR, 21.4 mo mOS (smaller BEACON dataset). Both are autologous CAR-Ts — ACE-723's ADC modality has a manufacturing and logistics moat, but efficacy bar is real.
Trial design cues
Ori-C101 registration Ph II design (randomized, GPC3+ enrichment, ≥2 prior lines) is the emerging template. GPC3 antigen loss and TGFβ elevation identified as resistance mechanisms — consider companion biomarker and dual-payload rationale for ACE-723 AD2C platform.
1L landscape churn = 2L opportunity
EMERALD-1 OS miss, rivo+camr FDA delay, and continued CheckMate 9DW / STRIDE competition mean 1L market is fragmenting. Post-IO 2L patients (the ACE-723 target) grow every quarter. REACH-2 (AFP-high), regorafenib, cabozantinib remain thin second-line options — ORRs typically <15%.
Actions to consider
- Update dashboard efficacy benchmarks with C-CAR031 Nature data and Ori-C101 BEACON update
- Verify BOXR-1030 program status (ACTIVE-NOT-RECRUITING at n=7 is a discontinuation signal)
- Track Ori-C101 registration Ph II NCT (likely to appear soon)
- Attend ESMO Madrid Oct 2026 for C-CAR031 abstract 1680RO update
- Model ACE-723 Ph1 design assumptions against emerging GPC3+ enrichment paradigm
Key sources:
Zhang et al., Nature (Jul 15 2026) ·
AbelZeta press release (Jul 23 2026) ·
BioWorld / Oricell Phase 2 (Jul 22 2026) ·
CancerNetwork / FDA CRL (Jul 10 2026) ·
ESMO GI 2026 EMERALD readouts ·
ASCO Post EMERALD-3 (Jul 25 2026) ·
HCC new therapies horizon review (Jul 15 2026) ·
Global solid-tumor CAR-T map (Jul 21 2026) ·
ClinicalTrials.gov API v2 (fetched 28 Jul 2026)
Phase Distribution
Modality Distribution
Line of Therapy Breakdown
Recruitment Status
Geographic Distribution — Top Countries by Trial Count
Efficacy Benchmarking
Approved therapy benchmarks (shaded) compared against investigational agents with published data.
Overall Response Rate (ORR)
Disease Control Rate (DCR)
Median PFS (months)
Median OS (months)
Comprehensive Efficacy Data
| Drug | Trial | Phase | Line | N | ORR | DCR | mPFS | mOS | Note |
|---|
Competitive Landscape Analysis
Modality vs Phase (Bubble Size = Enrollment)
Drug Class Distribution
Regional Trial Activity
Enrollment by Study Start Year
GPC3-Targeting Trials — Detailed Comparison
| Drug | Trial ID | Phase | Modality | Enrollment | Status | Company | Published Data |
|---|
Study Design Intelligence
Primary Endpoint Distribution
Randomization Breakdown
Child-Pugh Class Requirements
Comparator Analysis
Study Design Comparison Table
| Drug | Trial ID | Phase | Allocation | Masking | Primary EP | Comparator | Child-Pugh | ECOG | Prior Line Req. |
|---|
ACE-723 Positioning Analysis
Enter projected ACE-723 parameters to see how the program compares against the competitive landscape.
ACE-723 Parameters
Radar: ACE-723 vs Landscape Benchmarks
Competitive Ranking
Strategic Recommendations